Auris Medical Holding AG (NASDAQ:EARS) fell 7.2% during trading on Monday . The company traded as low as $3.95 and last traded at $3.97, with a volume of 164,094 shares changing hands. The stock had previously closed at $4.28.

A number of brokerages recently commented on EARS. Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Tuesday, July 12th. Jefferies Group restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. Finally, Leerink Swann restated a “buy” rating and issued a $12.00 price objective on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th.

The stock’s 50-day moving average price is $4.06 and its 200 day moving average price is $3.96. The company’s market capitalization is $130.11 million.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.